News

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...
President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...
The UK’s National Institute for Health and Care Excellence (NICE) on August 6 recommended the use of US pharma giant Merck & ...
Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...
Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.
In an interview with CURE, Clara Cirk shares the emotional weight of finishing chemo while facing ongoing immunotherapy and ...
Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust growth across various cancer indications worldwide. The drug alone accounts ...
Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...
Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...
Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...
Patients whose PD-L1 levels were above 50% — those for whom Keytruda already has the FDA’s blessing — survived a median of 20 months with Keytruda, compared with 12.2 months for chemotherapy.
Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...